Document is current
Any future updates will be listed below
-
Authors
Li, Xiaotong
Kumar, Sushant
Harmanci, Arif
Li, Shantao
Kitchen, Robert R.
Zhang, Yan
Wali, Vikram B.
Reddy, Sangeetha M.
Woodward, Wendy A.
Reuben, James M.
Rozowsky, Joel
Hatzis, Christos
Ueno, Naoto T.
Krishnamurthy, Savitri
Pusztai, Lajos
Gerstein, Mark https://orcid.org/0000-0002-9746-3719
-
Funding
Funding for this research was provided by:
SWOG HOPE Foundation Pilot Grant
SWOG HOPE Foundation Pilot Grant
National Institutes of Health (R01 HG 008126)
Breast Cancer Research Foundation
State of Texas Rare and Aggressive Breast Cancer Research Program Grant
National Institutes of Health T32 Training Grant (T32 CA 009666)
Conquer Cancer Foundation American Society of Clinical Oncology Young Investigator Award
Cancer Prevention and Research Institute of Texas Award (RR190020)
Genomic Health, Inc
- License Information
-
More Information
Article History
Received: 9 September 2020
Accepted: 25 March 2021
First Online: 26 April 2021
Declarations
:
: The study was approved by the Yale Cancer Center Human Investigations Committee (<i>HIC #1406014226</i>). The research conformed to the principles of the Helsinki Declaration. All patients provided written informed consent for genomic analysis of their cancer and germline DNA as well as participation in the study.
: All participants provided consent for publication.
: L.P. has received consulting fees and honoraria from Astra Zeneca, Merck, Novartis, Bristol-Myers Squibb Genentech, Eisai, Pieris, Immunomedics, Seattle Genetics, Clovis, Syndax, H3Bio, and Daiichi. C.H. is currently a full-time employee of Bristol-Myers Squibb. V.W. is currently a full-time employee of Janssen Pharmaceutical Companies of Johnson & Johnson. The remaining authors declare that they have no competing interests.
